Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Sep 14;4(8):761-765.
doi: 10.1016/j.jdcr.2018.05.022. eCollection 2018 Sep.

Nivolumab-induced alopecia areata: A reversible factor of good prognosis?

Myriam Lakhmiri  1   2   3 , Bénédicte Cavelier-Balloy  4 , Caroline Lacoste  4 , Charles Cassius  5 , Barouyr Baroudjian  1 , Julie Delyon  1   6   7 , Céleste Lebbé  1   6   7 , Pascal Reygagne  2
Affiliations
Case Reports

Nivolumab-induced alopecia areata: A reversible factor of good prognosis?

Myriam Lakhmiri et al. JAAD Case Rep. .
No abstract available

Keywords: AA, alopecia areata; CTLA-4, cytotoxic T-lymphocyte–associated antigen-4; ICI, immune checkpoint inhibitors; PD-1, programmed cell death protein-1; PD-L1, programmed death ligand-1; alopecia areata; anti–programmed cell death protein-1; drug adverse event; immune related; lung cancer; melanoma; nivolumab.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Nivolumab-induced AA before treatment in metastatic lung cancer (case 1).
Fig 2
Fig 2
Dermoscopy shows yellow and black dots and anisotrichia in nivolumab-induced AA used for metastatic lung cancer (case 1).
Fig 3
Fig 3
A, Nivolumab-induced AA before treatment in metastatic lung cancer (case 2). B, Nivolumab-induced AA regrowth after 3 months of treatment (case 2).
Fig 4
Fig 4
Dermoscopy shows yellow and black dots, anisotrichia, and poliosis in nivolumab-induced AA before treatment in lung cancer (case 2).
Fig 5
Fig 5
Histology shows perifollicular lymphocytic infiltrate and a follicular miniaturization in nivolumab-induced AA used for metastatic lung cancer (case 2).
Fig 6
Fig 6
A, Nivolumab-induced AA before treatment in metastatic melanoma (case 3). B, Nivolumab-induced AA regrowth after 9 months of treatment (case 3).
Fig 7
Fig 7
Dermoscopy shows yellow and black dots, anisotrichia, and poliosis in nivolumab-induced AA after treatment in metastatic melanoma (case 3).
Fig 8
Fig 8
Histology shows a miniaturization of hair with telogen follicles with a slight perifollicular lymphocytic infiltrate in nivolumab-induced AA used for metastatic melanoma (case 3).
Fig 9
Fig 9
A and B, Nivolumab-induced AA before treatment in metastatic melanoma. Clinical photographs show a typical patch of AA (case 4).
See this image and copyright information in PMC

References

    1. Azoury S.C., Straughan D.M., Shukla V. Immune checkpoint inhibitors for cancer therapy: clinical efficacy and safety. Curr Cancer Drug Targets. 2015;15:452–462. - PubMed
    1. Tsirigotis P., Savani B.N., Nagler A. Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies. Ann Med. 2016;48:428–439. - PubMed
    1. Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol. 2018;19:345–361. - PubMed
    1. Zarbo A., Belum V.R., Sibaud V. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. Br J Dermatol. 2017;176:1649–1652. - PMC - PubMed
    1. Weber J.S., Hodi F.S., Wolchok J.D. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35:785–792. - PubMed

Publication types

LinkOut - more resources